Even though our findings indicate the presence of additive cytotoxic effect in vitro but not in vivo synergistic effect, the combined treatment keeps the ability of dasatinib to abrogate relevant pro-tumor signaling (i.e., SRC/FAK signaling) and abolish invasive potential, while adding the potent capacity of EC-8042 to target CSC subpopulations and inhibit tumor growth, without any noticeable adverse interactions of both agents. This evidence concerns the gene SRC and neoplasm.